Nabla Bio
Edit

Nabla Bio

https://www.nabla.bio/
Last activity: 02.08.2025
Active
Categories: Artificial IntelligenceBioTechDesignDrugLearnMedtechPlatformUniversity
Nabla Bio is an autoverse platform of proprietary biologically informed machine learning that co-develops antibody drugs.
Mentions
16
Persons
9
Location: United States, Massachusetts, Boston
Employees: 1-10
Total raised: $37M
Founders name: Surge Biswas; Frances Anastassacos
Founders Related Locations: United States, Massachusetts, Boston

Investors 3

Funding Rounds 2

DateSeriesAmountInvestors
15.05.2024Series A$26M-
10.12.2021Seed$11M-

Persons 9

DateFirst NameLast NameTitleLinkedInLocation
-MarkDeSimoneSenior Res...linkedin.c...-
-SunitaSubramania...Senior Sci...linkedin.c...-
-SurgeBiswasCo-founder...linkedin.c...United Sta...
-PaytonUtzmanSenior Res...linkedin.c...-
-DevashishPrasadAssociate ...linkedin.c...-
-AdithyaParamasiva...Associate ...linkedin.c...-
-FrancesAnastassac...Cofounderlinkedin.c...-
-OwenMorrisseySoftware E...linkedin.c...-
-KarmanyaAggarwalML Scienti...linkedin.c...-

Mentions in press and media 16

DateTitleDescription
15.05.2024Nabla Bio Secures $26M Series A FundingNabla Bio, a Cambridge, MA-based company developing AI and wet-lab technologies, raised $26M in Series A funding. The round was led by Radical Ventures with participation from all existing investors, and strategic collaborations with AstraZ...
14.05.2024Nabla Bio Scores $26M Series A Financing Round CAMBRIDGE, MA, Nabla Bio, pioneers in generative protein design, today announced the close of a $26 million Series A financing. >> Click here for more funding data on Nabla Bio >> To export Nabla Bio funding data to PDF and Exc...
07.12.2021Nabla Bio raises $11M for an “end-to-end” antibody design platformNabla Bio, a Boston, Massachusetts based startup, announced a $11 million seed round on Monday. The company, founded in May 2020, is looking to enter the increasingly competitive space of antibody design, and manufacturing. Nabla Bio, in es...
07.12.2021Harvard spinout Nabla Bio nabs $11M for AI-driven antibody designAfter a decades-long tenure as the so-called father of synthetic biology, George Church, Ph.D., has developed something of a Midas touch when it comes to biotech and medtech startups. Among the latest of the serial entrepreneur’s projects i...
07.12.2021Harvard spinout Nabla Bio nabs $11M for AI-driven antibody designAfter a decades-long tenure as the so-called father of synthetic biology, George Church, Ph.D., has developed something of a Midas touch when it comes to biotech and medtech startups. Church and his team have gotten an early boost for the y...
06.12.2021Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody designSoftware is key to how therapeutic antibodies are discovered today. The founders of Nabla Bio say the next generation of antibodies will be designed rather than discovered, and these designs will be aided by artificial intelligence. The Har...
06.12.2021Better.com’s morale and SPAC merger success in question after CEO’s unruly commentsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, Term Sheeters. Paid Content What companies need to know about cloud modernization F...
06.12.2021Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture PartnersNabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round. The round was co-led by Khosla Ventures and Zetta Venture Partners, with participation from Fifty Years, Cantos Ventures, and others...
06.12.2021Nabla Bio Raises $11M in Seed FinancingNabla Bio, a Boston MA-based antibody design company, raised $11M in Seed funding. The round was led by Khosla Ventures and Zetta Venture Partners with participation from Fifty Years and Cantos Ventures. The company intends to use the funds...
06.12.2021Better.com’s morale and SPAC merger success in question after CEO’s unruly commentsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, Term Sheeters. Paid Content How A.I. can reshape jobs to enable more value-add From...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In